

Michael McClung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6141056/michael-mcclung-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210
papers

19,061
citations

70
h-index

136
g-index

235
ext. papers

21,781
ext. citations

6.6
avg, IF

6.61
L-index

#	Paper	IF	Citations
210	Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.. <i>Menopause</i> , 2022 , 29, 304-308	2.5	
209	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1225-1234	6.3	2
208	Skeletal responses to romosozumab after 12 months of denosumab. <i>JBMR Plus</i> , 2021 , 5, e10512	3.9	7
207	Denosumab for the treatment of osteoporosis 2021 , 1737-1755		0
206	Role of bone-forming agents in the management of osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 775-791	4.8	4
205	Osteoanabolic therapy for osteoporosis in women. <i>Climacteric</i> , 2021 , 1-7	3.1	0
204	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , 2020 , 26, 1-46	3.2	164
203	History of risedronate. <i>Bone</i> , 2020 , 137, 115407	4.7	3
202	A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. <i>Osteoporosis International</i> , 2020 , 31, 2231-2241	5.3	10
201	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1014-1021	6.3	10
200	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE. <i>Endocrine Practice</i> , 2020 , 26, 564-570	3.2	59
199	Bone Mineral Density After Transitioning From Denosumab to Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	33
198	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. <i>Bone Reports</i> , 2020 , 13, 100729	2.6	7
197	Abaloparatide followed by alendronate in women 80 years with osteoporosis: post hoc analysis of ACTIVExtend. <i>Menopause</i> , 2020 , 27, 1137-1142	2.5	3
196	Osteoporosis. <i>Lancet, The</i> , 2019 , 393, 364-376	40	578
195	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2443-2452	5.6	23
194	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , 2019 , 132, e771-e777	2.4	9

193	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 899-911	18.1	61
192	Efficacy and Safety of Osteoporosis Treatment 2019 , 43-57		2
191	Robust norms for neuropsychological tests of verbal episodic memory in Australian women. <i>Neuropsychology</i> , 2019 , 33, 581-595	3.8	11
190	Bone age as a correction factor for the analysis of trabecular bone score (TBS) in children. <i>Archives of Osteoporosis</i> , 2019 , 14, 26	2.9	4
189	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <i>Menopause</i> , 2018 , 25, 767-771	2.5	20
188	Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. <i>Calcified Tissue International</i> , 2018 , 102, 627-633	3.9	7
187	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1397-1406	6.3	99
186	Romosozumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , 2018 , 4, 11-15	2.3	39
185	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 190-198	6.3	306
184	Inflammation-Induced Bone Loss in the Rheumatic Diseases 2018 , 459-466		
183	Bisphosphonates for Postmenopausal Osteoporosis 2018 , 545-552		1
182	Sarcopenia and Osteoporosis 2018 , 498-504		
181	Drug holidays in women treated for postmenopausal osteoporosis. <i>Menopause</i> , 2018 , 25, 1152-1154	2.5	1
180	Cellular Bioenergetics of Bone 2018 , 1004-1011		
179	Interactions Between Muscle and Bone 2018 , 1055-1062		1
178	Gonadal Steroids 2018 , 194-204		
177	Advanced Techniques of Bone Mass Measurements and Strength in Adults 2018 , 260-271		1
176	Biochemical Markers of Bone Turnover in Osteoporosis 2018 , 293-301		0

175	Transplantation Osteoporosis 2018 , 424-435		1
174	Osteoporosis in Men 2018 , 443-449		
173	Effects on the Skeleton from Medications Used to Treat Nonskeletal Disorders 2018 , 482-486		
172	Obesity and Skeletal Health 2018 , 492-497		
171	Prevention of Falls 2018 , 526-533		1
170	Parathyroid Hormone and Abaloparatide Treatment for Osteoporosis 2018 , 559-566		
169	Management of Osteoporosis in Patients with Chronic Kidney Disease 2018 , 505-509		1
168	Clinical utility of anti-sclerostin antibodies. <i>Bone</i> , 2017 , 96, 3-7	4.7	12
167	Observations following discontinuation of long-term denosumab therapy. <i>Osteoporosis International</i> , 2017 , 28, 1723-1732	5.3	125
166	Denosumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , 2017 , 3, 8-17	2.3	14
165	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , 2017 , 130, 862.e1-862.e7	2.4	14
164	Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 263-270	3.8	49
163	Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2017 , 28, 2967-2973	5.3	22
162	Using Osteoporosis Therapies in Combination. <i>Current Osteoporosis Reports</i> , 2017 , 15, 343-352	5.4	20
161	Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The São Paulo Ageing & Health (SPAHE) Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1146-57	6.3	22
160	Other Safety Concerns 2016 , 279-293		
159	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , 2016 , 129, 221.e1-10	1.1-10	139
158	RE-INVIGORATING THE OSTEOPOROSIS MESSAGE. <i>Endocrine Practice</i> , 2016 , 22, 1130-1	3.2	

157	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1827-1834	6.3	52
156	Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. <i>Osteoporosis International</i> , 2015 , 26, 699-712	5.3	105
155	Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. <i>Osteoporosis International</i> , 2015 , 26, 327-37	5.3	6
154	Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. <i>Bone</i> , 2015 , 81, 122-130	4.7	37
153	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1335-42	5.6	80
152	New management options for osteoporosis with emphasis on SERMs. <i>Climacteric</i> , 2015 , 18 Suppl 2, 56-61	4.1	7
151	Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 46-54	6.3	59
150	Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1754-7	6.3	5
149	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1119-33	6.3	111
148	Response to: Comment on: "Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis". <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1939-40	6.3	3
147	Emerging Therapies for Osteoporosis. <i>Endocrinology and Metabolism</i> , 2015 , 30, 429-35	3.5	21
146	Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. <i>Journal of Clinical Densitometry</i> , 2014 , 17, 490-5	3.5	14
145	Romosozumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2014 , 370, 412-20	59.2	781
144	Creation of an age-adjusted, dual-energy x-ray absorptiometry-derived trabecular bone score curve for the lumbar spine in non-Hispanic US White women. <i>Journal of Clinical Densitometry</i> , 2014 , 17, 314-9	3.5	42
143	Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 158-65	6.3	85
142	Bone Health and Hormonal Contraception 2014 , 287-306		1
141	Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. <i>Osteoporosis International</i> , 2013 , 24, 293-9	5.3	23
140	A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. <i>Calcified Tissue International</i> , 2013 , 92, 59-67	3.9	6

139	Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. <i>Bone</i> , 2013 , 56, 482-8	4.7	51
138	Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 250-6	3.5	24
137	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. <i>American Journal of Medicine</i> , 2013 , 126, 13-20	2.4	326
136	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. <i>Osteoporosis International</i> , 2013 , 24, 227-35	5.3	92
135	Treatment of postmenopausal osteoporosis with delayed-release risedronate 35mg weekly for 2 years. <i>Osteoporosis International</i> , 2013 , 24, 301-10	5.3	30
134	Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 147-53	3.5	38
133	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 584-600	3.5	3
132	Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?. <i>Clinical Obstetrics and Gynecology</i> , 2013 , 56, 743-8	1.7	11
131	Denosumab for the Treatment of Osteoporosis 2013 , 1923-1934		
130	Preventing postmenopausal osteoporosis 2013 , 70-83		
129	Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013 , 5, 199-209	3.8	21
128	Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4691-701	5.6	40
127	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. <i>Menopause</i> , 2013 , 20, 130-7	2.5	30
126	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 687-93	6.3	139
125	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 211-8	6.3	103
124	Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. <i>Osteoporosis International</i> , 2012 , 23, 267-76	5.3	36
123	Femoral strength in osteoporotic women treated with teriparatide or alendronate. <i>Bone</i> , 2012 , 50, 165-70	4.7	85
122	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3161-9	5.6	138

121	To FRAX or not to FRAX. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1240-2	6.3	10
120	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , 2011 , 14, 1-21	3.5	8
119	Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. <i>Osteoporosis International</i> , 2011 , 22, 1725-35	5.3	71
118	Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 397-404	6.3	88
117	Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 242-51	6.3	196
116	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 530-7	6.3	155
115	Effects of denosumab on fracture and bone mineral density by level of kidney function. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 1829-35	6.3	225
114	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 394-402	5.6	111
113	ZOLEDRONOVAYA KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZALNOGO VOZRASTA S OSTEOPENIEY. <i>Osteoporosis and Bone Diseases</i> , 2011 , 14, 37-39 ^{0.8}		
112	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. <i>Endocrine Practice</i> , 2010 , 16, 1016-9	3.2	43
111	The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. <i>Journal of the American Dental Association</i> , 2010 , 141, 1365-70	1.9	76
110	Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 937-47	6.3	213
109	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. <i>Endocrine Practice</i> , 2010 , 16 Suppl 3, 1-37	3.2	263
108	Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. <i>Clinical Interventions in Aging</i> , 2009 , 4, 445-9	4	19
107	Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. <i>Bone</i> , 2009 , 44, 418-22	4.7	20
106	Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. <i>American Journal of Medicine</i> , 2009 , 122, 992-7	2.4	17
105	Denosumab for prevention of fractures in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , 2009 , 361, 756-65	59.2	2189
104	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009 , 64, 805-807	2.4	6

103	Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. <i>Obstetrics and Gynecology</i> , 2009 , 114, 999-1007	4.9	86
102	The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?. <i>Salud Publica De Mexico</i> , 2009 , 51 Suppl 1, S46-51	1.7	3
101	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. <i>Bone</i> , 2008 , 42, 36-42	4.7	81
100	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. <i>Bone</i> , 2008 , 43, 222-229	4.7	408
99	Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. <i>Contraception</i> , 2008 , 77, 67-76	2.5	112
98	Who Should Be Screened: Who Should Be Treated? 2008 , 1449-1460		
97	Fracture risk remains reduced one year after discontinuation of risedronate. <i>Osteoporosis International</i> , 2008 , 19, 365-72	5.3	178
96	Effects of risedronate on fracture risk in postmenopausal women with osteopenia. <i>Osteoporosis International</i> , 2008 , 19, 681-6	5.3	49
95	Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. <i>Osteoporosis International</i> , 2008 , 19, 1039-45	5.3	48
94	Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 1832-41	6.3	239
93	Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 4671- P ^{5.6}	5.6	70
92	Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. <i>Bone</i> , 2007 , 41, 122-8	4.7	136
91	Role of RANKL inhibition in osteoporosis. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 1, S3	5.7	51
90	Bisphosphonate therapy: To stop or not to stop?. <i>BoneKEy Osteovision</i> , 2007 , 4, 78-82		3
89	Yearly zoledronic acid in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 357, 712-3; author reply 714-5	59.2	54
88	Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 2631-7	5.6	118
87	Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 22-30	3.5	93
86	Denosumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2006 , 354, 821-31	59.2	931

85	Do current management strategies and guidelines adequately address fracture risk?. <i>Bone</i> , 2006 , 38, S13-7	4.7	24
84	Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. <i>Contraception</i> , 2006 , 74, 90-9	2.5	85
83	Bisphosphonates. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006 , 50, 735-44		15
82	Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. <i>Menopause</i> , 2006 , 13, 377-86	2.5	87
81	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , 2006 , 17, 159-66	5.3	29
80	Bisphosphonates and osteonecrosis of the jaw. <i>Annals of Internal Medicine</i> , 2006 , 145, 791-2; author reply 792	8	4
79	Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat?. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 148-63	3.5	7
78	Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 141-51	6.3	251
77	How to Interpret Surrogate Markers of Efficacy in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1263-1264	6.3	0
76	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1315-22	6.3	230
75	Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. <i>Endocrine Reviews</i> , 2005 , 26, 688-703	27.2	538
74	The relationship between bone mineral density and fracture risk. <i>Current Osteoporosis Reports</i> , 2005 , 3, 57-63	5.4	40
73	Osteopenia: to treat or not to treat?. <i>Annals of Internal Medicine</i> , 2005 , 142, 796-7	8	12
72	Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. <i>Archives of Internal Medicine</i> , 2005 , 165, 1762-8		337
71	Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study 2005 , 20, 141		23
70	Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4879-85	5.6	66
69	Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. <i>Journal of the American Geriatrics Society</i> , 2004 , 52, 1832-9	5.6	145
68	Official positions of the international society for clinical densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 3651-5	5.6	211

67	Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 11-8	6.3	76
66	Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. <i>Clinical Therapeutics</i> , 2004 , 26, 15-28	3.5	124
65	Changes in bone density and turnover after alendronate or estrogen withdrawal. <i>Menopause</i> , 2004 , 11, 622-30	2.5	83
64	Parathyroid hormone for the treatment of osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2004 , 59, 826-32	2.4	9
63	Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3482-6	5.6	79
62	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. <i>Endocrine Practice</i> , 2003 , 9, 544-64	3.2	290
61	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2003 , 1, 116-22	5.4	5
60	Pathogenesis of osteoporotic hip fractures. <i>Clinical Cornerstone</i> , 2003 , Suppl 2, S22-9		9
59	Bisphosphonates. <i>Endocrinology and Metabolism Clinics of North America</i> , 2003 , 32, 253-71	5.5	54
58	The menopause and HRT. Prevention and management of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003 , 17, 53-71	6.5	17
57	The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. <i>Bone</i> , 2003 , 32, 421-6	4.7	33
56	Risedronate Once A Week. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003 , 2, 421		
55	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2003 , 1, 116-122	5.4	1
54	The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , 2002 , 71, 103-11	3.9	274
53	Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , 2002 , 136, 742-6	8	87
52	Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. <i>Regulatory Toxicology and Pharmacology</i> , 2002 , 35, 320-6	3.4	27
51	The Long-Term Effect Of Specific Type II 5 α -Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial. <i>Journal of Urology</i> , 2002 , 167, 2105-2108	2.5	51
50	A national random survey of bone mineral density reporting in the United States. <i>Journal of Clinical Densitometry</i> , 2002 , 5, 3-9	3.5	11

49	How does raloxifene reduce fracture risk?. <i>Menopause</i> , 2002 , 9, 306-8	2.5	1
48	Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. <i>New England Journal of Medicine</i> , 2001 , 344, 333-40	59.2	1530
47	Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 4717-26	5.6	92
46	Review of risedronate in the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 2011-25	4	9
45	Multisite bone ultrasound measurement on North American female reference population. <i>Journal of Clinical Densitometry</i> , 2001 , 4, 239-48	3.5	25
44	Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1492-7	5.6	67
43	Bisphosphonates in osteoporosis: recent clinical experience. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 225-38	4	39
42	Relation between body composition and biochemical markers of bone turnover among early postmenopausal women. <i>Journal of Clinical Densitometry</i> , 2000 , 3, 365-71	3.5	5
41	Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1999 , 131, 935-42	8	125
40	Blood pressure and calcium intake are related to bone density in adult males. <i>British Journal of Nutrition</i> , 1999 , 81, 383-388	3.6	27
39	Therapy for fracture prevention. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 687-9	27.4	22
38	Osteology: further debate. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1017	6.3	
37	Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. <i>Osteoporosis International</i> , 1999 , 10, 207-13	5.3	60
36	Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. <i>Journal of Bone and Mineral Research</i> , 1999 , 14 Suppl 2, 74-8	6.3	6
35	Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. <i>Clinical Therapeutics</i> , 1999 , 21, 1025-44	3.5	168
34	Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1032-8	6.3	105
33	Evidence that increased calcium intake does not prevent early postmenopausal bone loss. <i>Clinical Therapeutics</i> , 1998 , 20, 933-44	3.5	29
32	Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. <i>New England Journal of Medicine</i> , 1998 , 338, 485-92	59.2	428

31	Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. <i>Annals of Internal Medicine</i> , 1998 , 128, 253-61	8	180
30	Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 265-74	5.6	143
29	Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. <i>American Journal of Medicine</i> , 1997 , 103, 291-7	2.4	119
28	A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. <i>American Journal of Clinical Nutrition</i> , 1996 , 64, 354-60	7	62
27	Osteoporosis from the Perspective of an Endocrinologist. <i>Baylor University Medical Center Proceedings</i> , 1996 , 9, 47-52	0.6	
26	Discrepancies in normative data between Lunar and Hologic DXA systems. <i>Osteoporosis International</i> , 1996 , 6, 432-6	5.3	159
25	Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. <i>Seminars in Arthritis and Rheumatism</i> , 1996 , 25, 361-72	5.3	70
24	Use of bone densitometry results for decisions about therapy for osteoporosis. <i>Annals of Internal Medicine</i> , 1996 , 125, 623	8	6
23	Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. <i>Bone</i> , 1996 , 19, 195S-198S	4.7	16
22	Prediction of fracture risk. I: Bone density. <i>American Journal of the Medical Sciences</i> , 1996 , 312, 257-9	2.2	27
21	Quality control of DXA instruments in multicenter trials. <i>Osteoporosis International</i> , 1995 , 5, 218-27	5.3	96
20	Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. <i>American Journal of Medicine</i> , 1995 , 99, 144-52	2.4	296
19	Tiludronate therapy for Paget's disease of bone. <i>Bone</i> , 1995 , 17, 493S-496S	4.7	39
18	Automated evaluation of hip axis length for predicting hip fracture. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1065-70	6.3	92
17	Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites. <i>Osteoporosis International</i> , 1994 , 4, 42-7	5.3	156
16	Densitometry of the radius using single and dual energy absorptiometry. <i>Calcified Tissue International</i> , 1994 , 54, 208-11	3.9	19
15	Measurement of body composition in the elderly: dual energy x-ray absorptiometry, underwater weighing, bioelectrical impedance analysis, and anthropometry. <i>Gerontology</i> , 1994 , 40, 332-9	5.5	20
14	Treating Paget's Disease of Bone 1992 , 2, 22-28		2

13	Enhanced precision with dual-energy X-ray absorptiometry. <i>Calcified Tissue International</i> , 1992 , 51, 14-7	3.9	117
12	The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. <i>Annals of Internal Medicine</i> , 1990 , 112, 29-34	8	181
11	Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 81-8	6.3	20
10	Calcium and cholecalciferol: effects of small supplements in normal men. <i>American Journal of Clinical Nutrition</i> , 1988 , 48, 127-30	7	20
9	Serum protein concentrations and bone mineral content in aging normal men. <i>American Journal of Clinical Nutrition</i> , 1987 , 46, 614-21	7	32
8	Mid-molecule parathyroid hormone assay comparison. <i>Clinical Biochemistry</i> , 1986 , 19, 41-5	3.5	2
7	Acute parathyroid hormone secretory dynamics: hormone secretion from normal primate and adenomatous human tissue in response to changes in extracellular calcium concentration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 62, 950-5	5.6	10
6	Peritonitis in children receiving continuous ambulatory peritoneal dialysis. <i>Pediatric Infectious Disease Journal</i> , 1983 , 2, 328-32	3.4	18
5	Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. <i>Clinical Endocrinology</i> , 1981 , 14, 145-52	3.4	16
4	Treatment of hyperthyroidism. <i>Annual Review of Medicine</i> , 1980 , 31, 385-404	17.4	6
3	Fine-needle aspiration cytology in the preoperative diagnosis of thyroid nodules. <i>Annals of Internal Medicine</i> , 1977 , 87, 265-9	8	83
2	Emerging Therapies 211-226		
1	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 1-11	3.7	1